Cognizant Technology Solutions Corporation (NASDAQ:CTSH) Logo

Ubs Global Asset Management Americas Inc increased Cognizant Tech Solutions Cl A (CTSH) stake by 12.46% reported in 2019Q3 SEC filing. Ubs Global Asset Management Americas Inc acquired 317,616 shares as Cognizant Tech Solutions Cl A (CTSH)’s stock declined 2.37%. The Ubs Global Asset Management Americas Inc holds 2.87M shares with $172.73 billion value, up from 2.55M last quarter. Cognizant Tech Solutions Cl A now has $33.90B valuation. The stock decreased 1.20% or $0.75 during the last trading session, reaching $61.91. About 1.56M shares traded. Cognizant Technology Solutions Corporation (NASDAQ:CTSH) has declined 9.71% since December 9, 2018 and is downtrending. It has underperformed by 9.71% the S&P500. Some Historical CTSH News: 14/05/2018 – Comgest Exits Criteo, Cuts Netease, Buys More Cognizant: 13F; 27/03/2018 – Cognizant Named Adobe’s 2017 Delivery Quality Partner of the Year; 07/05/2018 – Cognizant Tech Solutions 1Q Adjusted Operating Margin 20.3%; 07/05/2018 – Cognizant Tech Solutions Sees FY Rev $16.05B-$16.3B; 19/04/2018 – Cognizant Completes Acquisition Of Bolder Healthcare Solutions; 23/04/2018 – DJ Cognizant Technology Solutions Corp, Inst Holders, 1Q 2018 (CTSH); 07/05/2018 – Cognizant cuts profit forecast due to tax hit; 14/03/2018 – Glancy Prongay & Murray LLP Commences Investigation on Behalf of Cognizant Technology Solutions Corporation Investors (CTSH); 22/03/2018 – Cognizant And General Assembly To Launch No-Cost Digital Engineering Education Program; 15/05/2018 – CEO D’Souza Gifts 325 Of Cognizant Technology Solutions Corp

The stock of CRISPR Therapeutics AG (NASDAQ:CRSP) is a huge mover today! The stock decreased 7.16% or $5.18 during the last trading session, reaching $67.19. About 1.40 million shares traded or 56.90% up from the average. CRISPR Therapeutics AG (NASDAQ:CRSP) has risen 101.48% since December 9, 2018 and is uptrending. It has outperformed by 101.48% the S&P500. Some Historical CRSP News: 08/05/2018 – CRISPR Therapeutics 1Q Loss/Shr 62c; 16/04/2018 – CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018; 08/05/2018 – CRISPR THERAPEUTICS AG – HAS $341.8 MLN IN CASH AS OF MARCH 31, 2018; 08/05/2018 – CRISPR HAD $341.8M IN CASH AS OF MARCH 31; 30/05/2018 – CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease; 10/04/2018 – Crispr Therapeutics at Deutsche Bank Conference May 9; 13/04/2018 – CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018; 08/05/2018 – CRISPR THERAPEUTICS AG – QTRLY SHR LOSS $0.62; 26/03/2018 – Crispr Therapeutics Presenting at Conference Tomorrow; 08/05/2018 – CRISPR THERAPEUTICS AG – ON TRACK TO BEGIN CTX001 CLINICAL STUDY IN HEMOGLOBINOPATHIES IN 2018The move comes after 9 months negative chart setup for the $3.78 billion company. It was reported on Dec, 9 by Barchart.com. We have $63.16 PT which if reached, will make NASDAQ:CRSP worth $226.56 million less.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 gene-editing platform in Switzerland. The company has market cap of $3.78 billion. The CRISPR/Cas9 technology allows for changes to genomic DNA. It currently has negative earnings. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies.

More notable recent CRISPR Therapeutics AG (NASDAQ:CRSP) news were published by: Nasdaq.com which released: “CRSP Prices Offering At $64.50/Share – Nasdaq” on November 22, 2019, also Nasdaq.com with their article: “Healthcare Stocks That Hit New Highs (XBIT, DRNA, CRSP…) – Nasdaq” published on November 19, 2019, Nasdaq.com published: “Here’s Why CRISPR Therapeutics Stock Is Falling Today – Nasdaq” on November 21, 2019. More interesting news about CRISPR Therapeutics AG (NASDAQ:CRSP) were released by: Nasdaq.com and their article: “Here’s Why CRISPR Stocks Are Soaring Today – Nasdaq” published on November 19, 2019 as well as Nasdaq.com‘s news article titled: “Better Buy: CRISPR Therapeutics vs. Intellia Therapeutics – Nasdaq” with publication date: November 14, 2019.

Among 4 analysts covering CRISPR Therapeutics AG – Common Shares (NASDAQ:CRSP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CRISPR Therapeutics AG – Common Shares has $8000 highest and $5000 lowest target. $66.50’s average target is -1.03% below currents $67.19 stock price. CRISPR Therapeutics AG – Common Shares had 7 analyst reports since June 10, 2019 according to SRatingsIntel. The stock of CRISPR Therapeutics AG (NASDAQ:CRSP) earned “Outperform” rating by Oppenheimer on Tuesday, November 12. Oppenheimer maintained it with “Outperform” rating and $8000 target in Tuesday, November 26 report.

Analysts await CRISPR Therapeutics AG (NASDAQ:CRSP) to report earnings on February, 24. They expect $0.04 earnings per share, up 104.35% or $0.96 from last year’s $-0.92 per share. CRSP’s profit will be $2.25M for 419.94 P/E if the $0.04 EPS becomes a reality. After $2.40 actual earnings per share reported by CRISPR Therapeutics AG for the previous quarter, Wall Street now forecasts -98.33% negative EPS growth.

Investors sentiment increased to 0.78 in 2019 Q3. Its up 0.16, from 0.62 in 2019Q2. It improved, as 65 investors sold CTSH shares while 288 reduced holdings. 78 funds opened positions while 199 raised stakes. 474.01 million shares or 2.40% less from 485.65 million shares in 2019Q2 were reported. Kayne Anderson Rudnick Investment Management Limited Liability stated it has 0.01% of its portfolio in Cognizant Technology Solutions Corporation (NASDAQ:CTSH). Guinness Atkinson Asset Incorporated invested in 4.29% or 90,180 shares. Fulton Natl Bank Na holds 0.15% of its portfolio in Cognizant Technology Solutions Corporation (NASDAQ:CTSH) for 36,248 shares. Tower Bridge Advsr has invested 0% in Cognizant Technology Solutions Corporation (NASDAQ:CTSH). Oakbrook Investments Limited Liability Co holds 30,400 shares or 0.12% of its portfolio. The Minnesota-based Stonebridge Cap Advisors Limited Liability Company has invested 0.03% in Cognizant Technology Solutions Corporation (NASDAQ:CTSH). Halsey Associates Ct accumulated 0.28% or 29,293 shares. Architects holds 0% or 161 shares. Ftb Advsr holds 0.44% in Cognizant Technology Solutions Corporation (NASDAQ:CTSH) or 92,801 shares. Directions Inv Ltd Liability holds 0.01% in Cognizant Technology Solutions Corporation (NASDAQ:CTSH) or 464 shares. Aperio Grp Incorporated Lc stated it has 0.09% in Cognizant Technology Solutions Corporation (NASDAQ:CTSH). Thomas White Ltd reported 145,568 shares. 180 were accumulated by Mitsubishi Ufj Securities Communication Ltd. Telemus Capital Lc reported 19,261 shares. Mu Invests reported 3.07% of its portfolio in Cognizant Technology Solutions Corporation (NASDAQ:CTSH).

More notable recent Cognizant Technology Solutions Corporation (NASDAQ:CTSH) news were published by: Finance.Yahoo.com which released: “Cognizant Technology Solutions (CTSH): Are Hedge Funds Right About This Stock? – Yahoo Finance” on November 26, 2019, also Nasdaq.com with their article: “Ex-Dividend Reminder: Manulife Financial, Newmark Group and Cognizant Technology Solutions – Nasdaq” published on November 14, 2019, Prnewswire.com published: “Cognizant Named An AWS Outposts Partner – PRNewswire” on December 03, 2019. More interesting news about Cognizant Technology Solutions Corporation (NASDAQ:CTSH) were released by: Prnewswire.com and their article: “New Report Names Cognizant a Leader in Software Product Engineering – PRNewswire” published on November 14, 2019 as well as Nasdaq.com‘s news article titled: “Cognizant (CTSH) Q3 Earnings Beat, Revenues Increase Y/Y – Nasdaq” with publication date: October 31, 2019.

Cognizant Technology Solutions Corporation (NASDAQ:CTSH) Institutional Positions Chart




Source link